

## **Curriculum Vitae**

### **Formazione Scientifica:**

Laurea specialistica Biologia Cellulare e Molecolare, 12/03/09, Università Tor Vergata, 110/110 *cum laude*.

PhD Biologia Cellulare e Molecolare, 3/04/13, Università Tor Vergata.

Post-DOC presso il laboratorio di Farmacologia ed Epigenetica del Dott. Puri, Istituto S. Lucia, RM.

### **Pubblicazioni:**

1)Palacios D, Mozzetta C, **Consalvi S**, et al. TNF/p38 $\alpha$ /polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. *Cell Stem Cell* 2010;

2)Mozzetta C\*, **Consalvi S\***, et al. Selective control of Pax7 expression by TNF-activated p38 $\alpha$ /polycomb repressive complex 2 (PRC2) signaling during muscle satellite cell differentiation. *Cell Cycle* 2011;

3)**Consalvi S**, et al. Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases. *Mol Med* 2011;

4)Forcales SV, Albin S, Giordani L, Cignolo L, Saccone V, **Consalvi S**, et al. Signal-dependent incorporation of MyoD-BAF60c into Brg1-based SWI/SNF chromatin-remodelling complex. *EMBO J* 2011;

5)Mozzetta C\*, **Consalvi S\***, et al. Fibroadipogenic progenitors mediate the ability of HDAC inhibitors to promote regeneration in dystrophic muscles of young, but not old mdx mice. *EMBO Mol Med* 2013;

6)**Consalvi S**, et al. Preclinical studies with pharmacological treatment of murine model of Duchenne Muscular Dystrophy with the Histone Deacetylase inhibitor Givinostat. *Mol Med* 2013;19:79-87.

7)Saccone V\*, **Consalvi S\***, et al. HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles. *Genes Dev* 28 2014;

8)**Consalvi S**, et al. Rationale for a pharmacological therapy of Duchenne Muscular Dystrophy: an epigenetic perspective. *Epigenomic*. Accepted.

9)Giordani L, Sandonà M, Rotini A, Puri PL, **Consalvi S**^, Saccone V. Muscle-specific microRNAs as biomarkers of Duchenne Muscular Dystrophy progression and response to therapies. *Rare Disease*. Accepted.

\*: **Co-autore**

^: **Co-corresponding**

**Brevetti:** Inventore del Diethyl-[6-(4-Hydroxycarbamoyl-Phenyl-Carbamoyloxy-Methyl)-Naphthalen-2-Yl-Methyl]-Ammonium Chloride per l'uso nella Distrofia Muscolare di Duchenne (proprietà intellettuale). Patent Number: 12715734.5-1464